Introduction
============

Marek's disease (MD) is a lymphoproliferative disease of chickens caused by Marek's disease virus (MDV) with pathological features including mononuclear cell-infiltration in the peripheral nerves, skin, and muscle (Davison and Nair, [@B15]). MDV is classified into the *Mardivirus* genus due to its genome content (Davison, [@B14]) and biological effect on lymphocytes like EBV (Epstein, [@B17]). MDV life cycle in its host can be divided into four phases, including an early cytolytic phase from 2 to 7 days post infection (dpi), a latency phase around 7--10 dpi, a late cytolytic phase starting from 18 dpi and a proliferation phase after 28 dpi (Calnek, [@B9], [@B10]). Although MD is controlled by vaccination, the virulence of MDV has being evolved over time and resulted in more severe brain edema and acute deaths even after vaccination (Witter, [@B41]; Osterrieder et al., [@B33]). MD remains a problem in the poultry industry worldwide (Churchill et al., [@B12]). Since the inheritance and resistance to MD was first observed (Asmundson and Biely, [@B4]), MD-resistant and -susceptible chickens have been bred by those including Stone (lines 6 and 7; Bacon et al., [@B5]), Hutt, and Cole (lines N and P; Davison and Nair, [@B15]). Nowadays, the selection of genetically disease resistant chickens is especially important in MD control. A better understanding in the mechanisms of MD-resistance and -susceptibility should be of great value in developing better strategies to further prevent and control MD.

In recent years, most of the studies are focused on genetic variations between MD-resistant and susceptible chickens (Gilmour et al., [@B21]; Fredericksen et al., [@B20]; Kaiser et al., [@B26]; Sarson et al., [@B36]). However, little is done on epigenetic differences between the two kinds of chickens. Epigenetics is the study of alterations in phenotypes that are not brought about by changes in DNA sequences, but by factors including DNA methylation, histone modifications, and so on (Allis et al., [@B3]). DNA methylation is known as a post-replication modification found on the 5-C position of cytosine mainly in CpG dinucleotides, generated and maintained by three methyltransferases -- DNMT1, DNMT3a, and DNMT3b (Allis et al., [@B3]). In mammals, DNA methylation was found playing important role in development, imprinting, carcinogenesis, and other diseases (Feinberg and Tycko, [@B18]; Feng et al., [@B19]). Notably, we found two DNA mutations in *DNMT3b* (Yu et al., [@B45]) and a higher promoter methylation level of *ALVE* and *TVB* in the spleen of MD-susceptible chickens (L7~2~) compared to that of MD-resistant chickens (L6~3~; Yu et al., [@B46]), and the methylation level in *CD4* promoter region was down-regulated in the former but not in the later at 21 dpi (Luo et al., [@B30]).

To advance the understanding of functional patterns of DNA methylation in disease resistance or susceptibility, we extended the scope of examination to 18 interested genes, which include *STAT1*, *CIITA*, *NK-lysin*, *CD44*, *IL12*, and *GH1* that the expression levels of these gene are alterable upon MDV challenge (Liu et al., [@B28]; Abdul-Careem et al., [@B1]; Parcells and Burgess, [@B34]; Sarson et al., [@B36],[@B37]; Heidari et al., [@B24]; Thanthrige-Don et al., [@B39]). Some of the 18 genes were also chosen based on our previous temporal microarray data, which include *FABP3*, *HDAC9*, *IL28RA*, *MON2*, and *THBS2* (Luo et al., [@B30]; Yu et al., [@B44]).

Materials and Methods
=====================

Animals, challenge trial, and sample collection
-----------------------------------------------

Specific pathogen free chickens from two highly inbred White Leghorn lines, the L6~3~ and L7~2~, were used. Chickens from each of the lines were divided into two groups. One group was challenged with a very virulent plus MDV (vv + MDV), 648A passage 40, intra-abdominally at day 5 post hatch at a 500 plaque-forming unit (PFU) dosage, the other was not challenged and was assigned as the control group. Fresh spleen samples were respectively collected at 5, 10, and 21 dpi from both groups, and placed in RNAlater (Qiagen, Valencia, CA, USA) immediately, and then stored at −80°C.

All of the experimental chickens were challenged and maintained in a BSL-2 facility at the Avian Disease and Oncology Laboratory (ADOL), East Lansing, Michigan. The chickens were handled closely following animal usage procedures established by the ADOL ACUC committee.

DNA extraction, bisulfite treatment, and pyrosequencing
-------------------------------------------------------

DNA was extracted from 20 ∼ 30 mg spleen by NucleoSpin^®^ Tissue Kits (Macherey-Nagel, Bethlehem, PA, USA). Bisulfite treatment of 1 μg DNA per chicken was performed using EZ DNA Methylation-Gold Kit™ (ZYMO Research, Irvine, CA, USA). Primers for PCR and pyrosequencing were designed with PSQ Assay Design software (Biotage, Charlotte, NC, USA; Table [A1](#TA1){ref-type="table"} in Appendix). For cost saving purposes, a universal primer (5′-GGGACACCGCTGATCGTTTA-3′) was used in the PCR assays (Yu et al., [@B45]). PCR was carried out using Hotstar Taq DNA polymerase (Qiagen, Valencia, CA, USA) in 20 μl reactions in iCycler (Bio-Rad, Hercules, CA, USA) Detection System as follows: samples were denatured at 95°C for 15 min, followed by 50 cycles at 95°C for 30 s, 55--60°C for 30 s, 72°C for 30 s, and then extended at 72°C for 10 min. DNA methylation level analysis was performed on the Pyro Q-CpG system (PyroMark ID, Biotage, Charlotte, NC, USA) as previously described (Colella et al., [@B13]; Yu et al., [@B45]).

RNA extraction and quantitative real-time RT-PCR
------------------------------------------------

RNA from 30 ∼ 50 mg spleen was extracted using the RNeasy Mini Kit (Qiagen, USA). Reverse transcription was carried out in 20 μl with 1 μg of total RNA by using SuperScriptTM III Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) and oligo (dT)12--18 primers (Invitrogen, Carlsbad, CA, USA). Primers (Table [A2](#TA2){ref-type="table"} in Appendix) for quantitative real-time RT-PCR were designed using Primer3 online primer designer system[^1^](#fn1){ref-type="fn"}. Quantitative real-time RT-PCR was performed on the iCycler iQ PCR system (Bio-Rad, USA) in a final volume of 20 μl using QuantiTect SYBR Green PCR Kit (Qiagen) with following procedures: denatured at 95°C for 15 min, followed by 40 cycles at 95°C for 30 s, 55--60°C for 30 s, 72°C for 30 s, then extended at 72°C for 10 min. Each reaction was replicated. The housekeeping gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used to normalize the loading amount of cDNA.

Functional analysis and statistics
----------------------------------

The GO Biological Process analysis of the genes was analyzed by PANTHER[^2^](#fn2){ref-type="fn"}. Student's *t*-test was used to analyze the differences of the promoter methylation level and the gene expression before and after MDV infection.

Results
=======

Differential methylation patterns between the L6~3~ and L7~2~
-------------------------------------------------------------

To determine the different methylation levels of genes between the MD-resistant L6~3~ and the MD-susceptible L7~2~ chickens, we analyzed the DNA methylation status of promoters for 18 genes by bisulfite pyrosequencing method. The results showed that most of the 18 genes, including *LATS2*, *MON2*, *IL28RA*, *STAT1*, *CD44*, *H2Ac*, *TNFSF10*, *IL12*, *FABP3*, and *CIITA*, were hypomethylated (methylation level \<40%); few of them, *ITGB5*, *THBS2*, and *HDAC9*, had intermediate methylation level (between 40% and 60%), and the rest (*IGF2*, *GH1*, *NK-lysin*, and *TGF*β*3*) had hypermethylation methylation level (\>60%) in the control groups of both lines (Table [A3](#TA3){ref-type="table"} in Appendix). However, some of the CpGs of *CD82* had a very low methylation level (\<10%) and others had an intermediate methylation level (Table [A3](#TA3){ref-type="table"} in Appendix).

Differential promoter methylation levels were observed for *ITGB5*, *THBS2*, *HDAC9*, *IL12*, *CD44*, *H2AC*, and *TNFSF10* between the L6~3~ and L7~2~, As showed in Figure [1](#F1){ref-type="fig"}, the methylation levels in all the tested CpG sites of the *ITGB5*, *THBS2*, *HDAC9*, *IL12*, *H2AC* were significantly higher in L7~2~ than in L6~3~ (*P* \< 0.05; Figures [1](#F1){ref-type="fig"}A--E). However, some of the CpG sites in *CD44* (CpG 2 and 4) and *TNFSF10* (CpG 5) had higher level of methylation (*P* \< 0.05), while some others (*CD44* CpG 3; *TNFSF10* CpG 1 and 3) had lower methylation levels in L6~3~ than L7~2~ (*P* \< 0.05; Figures [1](#F1){ref-type="fig"}F,G).

![**Differentiated promoter methylation levels between the L6~3~ and L7~2~ chickens observed in *ITG*β5 (A), *THBS2* (B), *HDAC9* (C), *IL12* (D), *H2Ac* (E), *CD44* (F), and *TNFSF10* (G). The promoter methylation levels of the genes in spleen were examined by pyrosequencing**. The absolute methylation level for each CpG site from pyrosequencing result was plotted. Solid line: L6~3~; dashed line: L7~2~. \**P* \< 0.05, \*\**P* \< 0.01. *N* = 12 for each group. Error bar = SEM.](fgene-03-00020-g001){#F1}

To test if the differential promoter methylation levels of these genes are related with gene expression, we randomly chose two genes, *ITGB5* and *H2Ac*, and did quantitative RT-PCR. We found that the expression levels of the two genes, whose promoter methylation is higher in L7~2~ chicken, is lower in these chickens (Figure [2](#F2){ref-type="fig"}).

![**Expression of *ITGB5* (A) and *H2Ac* (B) in non-infected chicken samples**. *N* = 4 for each group. Error bar = STD.](fgene-03-00020-g002){#F2}

Functional analysis of the genes (Figure [3](#F3){ref-type="fig"}) showed that, in comparison to the whole gene set we examined in this experiment, genes with lower methylation levels in L6~3~ are mainly enriched in cellular component organization, response to stimulus, cell adhesion, and immune system process. In contrast, an under-enrichment of these genes was shown in cell communication, transport, system process, reproduction, and developmental process. For genes with a varied methylation levels between L6~3~ and L7~2~, they are over-represented in functions of cell adhesion and immune system process. However, for the genes with similar methylation between the L6~3~ and L7~2~, no under or over-represented biological functions was identified.

![**Functional analysis of the genes by PANTHER**.](fgene-03-00020-g003){#F3}

Differential DNMT1, DNMT3a, and DNMT3b expression induced by MDV challenge
--------------------------------------------------------------------------

To explore how MDV challenge induces DNA methylation alteration, we first checked if the expressions of the methylation agents, three methyltransferases (*DNMT1*, *DNMT3a*, and *DNMT3b*), were influenced over three time points (5, 10, and 21 dpi), which represent the early cytolytic, latent, and later cytolytic phase of the virus life cycle in the host cells, respectively. Interestingly, similar trends of expression changes were observed at 5 and 10 dpi for all three DNMTs in the MDV challenged chickens of both lines (Figure [4](#F4){ref-type="fig"}), while at 21 dpi, the changes were much more complicated. At 21 dpi, the *DNMT1* was significantly up-regulated in the infected L7~2~ chickens compared to the L7~2~ control group (*P* \< 0.05). The *DNMT1* was remained unchanged, however, between the infected and uninfected L6~3~ groups (*P* \> 0.05; Figure [4](#F4){ref-type="fig"}A). For *DNMT3a*, no expression difference was observed at 21 dpi between the infected and non-infected groups of both lines (*P* \> 0.05; Figure [4](#F4){ref-type="fig"}B). However, the *DNMT3b* was significantly down-regulated in the infected group of L6~3~ at 21 dpi (*P* \< 0.05), but no differential expression was observed in L7~2~ (Figure [4](#F4){ref-type="fig"}C). Overall, the expression levels of all the three DNMTs were significantly inducible by MDV infection, but with varied alteration trends and extents were found over different time points and between the infected and non-infected groups as well as between the chicken lines.

![**Expression of DNA methyltrasferase genes after MDV infection**. The expression of three DNA methyltrasferase genes, *DNMT1* **(A)**, *DNMT3a* **(B)**, and *DNMT3b* **(C)**, were tested by quantitative real-time RT-PCR at 5, 10, and 21 dpi in chicken spleen both resistant and susceptible to MD. The relative expression level was normalized to GAPDH gene. Black: non-infected; white: infected. \**P* \< 0.05, \*\**P* \< 0.01. *N* = 4 for each group. Error bar = SEM.](fgene-03-00020-g004){#F4}

Aberrant methylation level induced by MDV infection
---------------------------------------------------

To further study DNA methylation dynamic response to MDV infection, we tested the promoter methylation of the 18 genes on 5, 10, and 21 dpi. Pairwise comparison was performed between the infected and non-infected age-matched sample groups of each chicken line for each of the CpG sites. Significant methylation level changes (*P* \< 0.05) were detected at one or more CpG sites in all of the genes except *THBS2* gene after MDV challenge. The methylation level changes of the examined genes were under 30%. The MDV-induced DNA methylation changes for *CIITA*, *NK-lysin*, *FABP3*, and *ITGB5* were 10% above their unchallenged counterpart for each of the CpG sites. More than 10% methylation change was found in *HDAC9* at 5 dpi and 7--10% changes at 21 dpi in L7~2~. Most of the genes (12/17) had significant methylation change (*P* \< 0.05) at more than one time point (Table [A4](#TA4){ref-type="table"} in Appendix; Figure [5](#F5){ref-type="fig"}), except for *IL12*, *TNFSF10*, and *ITGB5*, which were only changed at 5 dpi, and *CD44*, *LATS2*, *CIITA*, which were only changed at 21 dpi. In contrast between the two lines of chickens, more genes in L6~3~ had significant methylation changes at 5 dpi, while more genes were observed with significant methylation changes in L7~2~ at 10 and 21 dpi (Figure [6](#F6){ref-type="fig"}).

![**Venn Diagrams of the number of genes have the methylation change at different time points and in different chicken lines. (A) The number of genes has the methylation change at 5, 10, and 21 dpi**. **(B--D)** The number of genes has the methylation change between L6~3~ and L7~2~ at 5, 10, and 21 dpi respectively.](fgene-03-00020-g005){#F5}

![**Functional analysis of the genes have different methylation change between L6~3~ and L7~2~ at 5, 10, and 21 dpi by PANTHER**.](fgene-03-00020-g006){#F6}

Differentially methylation changes due to MDV challenge
-------------------------------------------------------

To compare the contents of the methylation change between L6~3~ and L7~2~, the mean methylation change of all the CpG sites was calculated for each gene. Seven out of the 18 genes (*HDAC9*, *GH*, *STAT1*, *CIITA*, *FABP3*, *LATS2*, and *H2Ac*) showed significant differentially averaged methylation changes (*P* \< 0.05) between the two lines of chickens (Table [1](#T1){ref-type="table"}; Figure [A1](#FA1){ref-type="fig"} in Appendix). Functional analysis of the genes with temporal methylation changes revealed that the genes, related to apoptosis, immune system process, and response to stimulus, were over-represented at 5 dpi (Figure [6](#F1){ref-type="fig"}). However, genes, involved in enrichment of cell communication, were shown at 10 dpi; Genes, involved in functionality of cell cycle, cellular component organization, and transport, were over-represented at 10 and 21 dpi.

###### 

**Differential DNA methylation change between L6~3~ and L7~2~ after MDV challenge**.

  Time points (dpi)   Gene name   DNA methylation level change   *P* value   
  ------------------- ----------- ------------------------------ ----------- --------
  5                   *GH*        −4.71                          2.95\*      0.0146
                      *CIITA*     1.95                           −7.51\*     0.0298
                      *STAT1*     −0.95\*\*                      0.42        0.0244
                      *H2Ac*      1.11\*\*                       2.62\*\*    0.0306
  10                  *FABP3*     4.37\*\*                       −9.21\*\*   0.0002
                      *LATS2*     −0.01                          0.48\*\*    0.0409
                      *H2Ac*      2.53\*\*                       −0.56       0.0044
  21                  *HDAC9*     3.16\*\*                       7.92\*\*    0.0273
                      *GH*        0.83                           6.07\*\*    0.0096
                      *FABP3*     −1.76                          4.70\*\*    0.0117
                      *H2Ac*      0.78\*\*                       −1.36       0.0211

*\**P* \< 0.05, \*\**P* \< 0.01*.

Discussion
==========

The development of disease resistance has long been a very important strategy for control of diseases in farm animals (Bishop et al., [@B8]; Luo et al., [@B29]). A better understanding on the mechanisms of disease resistance will facilitate breeding of more disease resistant animals, help to better control diseases in farm animal and also provide better models to learn disease control strategies for humans. Since the establishment of the non-MHC associated MD-resistant and -susceptible chicken lines (Line 6 and Line 7), lots of experiments have been done to elucidate the genetic mechanism of MD-resistance between the two lines of chickens (Gilmour et al., [@B21]; Fredericksen et al., [@B20]; Kaiser et al., [@B26]; Sarson et al., [@B36]). However, not until recently, our lab started to explore their epigenetic differences between the chicken lines, which provides evidence that DNA methylation may be involved in MD-resistance or -susceptibility (Yu et al., [@B45],[@B46]; Luo et al., [@B30]). As we know, although the functions of DNA methylation in development, imprinting *etc*. were reported in mammals, it's still unclear about its function in disease resistance. Previous study in human (Jelinek et al., [@B25]) and plant (Akimoto et al., [@B2]) showed that individuals with a higher DNA methylation level in some particular genes are susceptible to diseases or bacterial infection, which is consistent with our finding that a higher methylation level of several genes (*ITGB5*, *THBS2*, *HDAC9*, *IL12*, and *H2Ac*) were shown in MD-susceptible (L7~2~) chickens. However, variable methylation level of *CD44* and *TNFSF10* between L6~3~ and L7~2~ indicated that the hypermethylation in susceptible chickens is not genome-widely. Functioning classification showed that the hypermethylated genes in susceptible chicken are showing functions of cellular component organization, response to stimulus, cell adhesion, and immune system process. Interestingly, hypermethylation of genes functioning in regulating cell adhesion was very important for the development of various cancers in human (Katto and Mahlknecht, [@B27]). Furthermore, expression analysis of the hypermethylated genes in the susceptible chickens showed a lower expression of these genes. The results indicated that there are specific pathways that may involve in MD-susceptibility or -resistance through hyper- or hypo-methylation of the genes included. In the future, a genome-wide DNA methylation research will be designed, which will help us explore the mechanisms further.

In previous study, the DNA methyltransferase (DNMTs) were usually found up-regulated by virus infection in human cells, like SV40 (Chuang et al., [@B11]) and EBV (Tsai et al., [@B40]). However, dynamic change of *DNMTs* expression was observed *in vivo* during MD life cycle in chicken. The *DNMTs* were first down-regulated at 5 dpi and then up-regulated at 10 dpi in both L6~3~ and L7~2~ chickens. Furthermore, different regulations of *DNMTs* were observed between the MD-resistant and -susceptible chickens at 21 dpi, indicating that late cytolytic phase is a critical time for *DNMTs* function in DNA methylation process or tumorigenesis. However, the *DNMTs* expression change was not necessary for the change of the methylation level change in the genes we studied. The correlation between *DNMTs* expression and methylation is upon chickens and time point. There are several reasons for that: First, other epigenetic mechanisms involve in the methylation change during MDV infection; second, the changed dosages of *DNMTs* are not efficient for the change of methylation on these genes; third, other functions of DNMTs involve. Except for establishing and maintaining the DNA methylation in cells, DNMTs also have other functions. The finding that *DNMT1* was only up-regulated in MD-susceptible chicken is consistent with the observation that DNMT1 is necessary for establishing and maintaining the transformation state of cells (Bakin and Curran, [@B7]; Robert et al., [@B35]). Similarly, *DNMT3B* deficient mouse embryo fibroblasts were found resistant to virus induced transformation (Soejima et al., [@B38]), which is consistent with our finding that the down-regulation of *DNMT3b* was only shown in MD-resistant chicken.

Abnormal DNA methylation is a common feature of human cancer. The fact is that DNA methylation started to be changed from very early stage of transformation process and a stepwise or dynamic change was happened during carcinogenesis (Ehrlich, [@B16]; Novak et al., [@B32]). Furthermore, DNA methylation modifications at the promoter regions of genes play a critical role in the intricate host--virus interaction network (Young et al., [@B43]; Zheng et al., [@B47]). From our results, the dynamic DNA methylation change during MD progression not only indicated an interaction between MDV and host gene, but also revealed the genes with aberrant methylation level may also involve in virus induced transformation process. During MDV life cycle in chicken spleen, 5 dpi is the early cytolytic phase when B cells and some T cells were targeted by MDV (Osterrieder et al., [@B33]). Virus infection in this stage provokes some apoptosis, lymphoid lesion, and inflammation responses in the immune organ (Morimura et al., [@B31]; Baigent and Davison, [@B6]). Different methylation change in genes enriched in apoptosis, immune system process, and response to stimulus suggested that the expression of these genes maybe differentially regulated between the MD-resistant and -susceptible chickens, which show different response to MDV infection. Although 10 and 21 dpi represent the latency and later cytolytic or transformation stage of MDV infection, it's very difficult to differentiate them very clearly *in vivo* since the latently infected cells can be mixed with the transformed cells (Davison and Nair, [@B15]). So we found some function enrichments like cell communication and transport are shared at 10 and 21 dpi. Genes over-represented in cell cycle and cell communications have different DNA methylation changes in L6~3~ and L7~2~ chicken. Since genes involve in cell cycle and cell communication play important role in carcinogenesis (Yamasaki et al., [@B42]; Hanahan and Weinberg, [@B22], [@B23]), these results suggested that DNA methylation may participate in MD-resistance by disrupting pathways intriguing tumor formation.

In conclusion, we found DNA methylation heterogeneity between the MD-resistant L6~3~ and -susceptible L7~2~ chickens. The hypermethylation of genes involved in cellular component organization, response to stimulus, cell adhesion, and immune system process may play important role in MD-susceptibility. Different from other viruses, MDV induces a dynamic expression change in *DNMTs*. Differential methylation changes are observed between resistant and susceptible chickens after MDV infection. All in all, the differential DNA methylation levels and DNA methylation level change induced by MDV challenge between the lines of chickens suggested that DNA methylation may play a role in host resistance and/or susceptibility to MD.
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###### 

**Primers for pyrosequencing analysis of promoter methylation**.

  Genes        Accession No.   Primers      Sequence
  ------------ --------------- ------------ --------------------------------------------------------------------------------------------------------
  *ITGB5*      NM_204483       F            5′-GGGACACCGCTGATCGTTTA YGTGYGGAGTTYGTAGAGAT-3′
                               R            5′-CCCTTAAAAACTATCTCRTTCCA-3′
                               Sequencing   5′-TCTCRTTCCAATTATACAC-3′
                               Assay        5′-RACRCTACCACCCRCTACRT-3′
  *CD82*       NM_001008470    F            5′-AGCGTTGYGAGTTTTATAGAAGTG-3′
                               R            5′-GGGACACCGCTGATCGTTTA AACCCTCRCTCRACTACTTTACC-3′
                               Sequencing   5′-AAGTGAGAATAATGTAATGG-3′
                               Assay        5′-TAGYGGTTAGTAGTTYGGTATTTYGTTGTTATYGTAGYGTTGTAATYGTT-3′
  *HDAC9*      NM_001030981    F            5′-TTGGGATATGGGTTGTCGAAAT-3′
                               R            5′-GGGACACCGCTGATCGTTTA GCTAATACTCTCGTTCGCAACATS′
                               Sequencing   5′-TGGGTTGTCGAAATAGTT-3′
                               Assay        5′-TYGYGGGATTGTTGTGYGTGGGYGYGGTAGAAATTATGTTGCGAACGAGA-3′
  *STAT1*      NM001012914     F            5′-TGTAAYGAAGTAAAATAGGYGAGA-3′
                               R            5′-GGGACACCGCTGATCGTTTA TCAACCTACACTACRCAACCTAA-3′
                               Sequencing   5′-TAAAATAGGCGAGATATAAG-3′
                               Assay        5′-TAYGYGAGTYGTTYGYGAGGTAGGGTCGTT-3′
  *TGFB5*      NM_205454       F            5′-GYGAGGATATTTATTTGGAAGAG-3′
                               R            5′-GGGACACCGCTGATCGTTTA CCCAAAAAATATCACCTCCAAT-3′
                               Sequencing   5′-GAGTTTGGGTTGGGTA-3′
                               Assay        5′-TAYGTAGTATTYGGAATTTTGTTYGAAATAGGTTGGTGTTGTTTTTTTTTG YGGAGGATA YGTTAAAGYG-3′
  *Nk-lysin*   NM001044680     F            5′-GYGTTAGTTGAATTTTAGAGTTTAAAG-3′
                               R            5′-GGGACACCGCTGATCGTTTA TTTATAAATTTTTCTCCACTACTACTAAT-3′
                               Sequencing   5′-AATTTTAGAGTTTAAAGGGA-3′
                               Assay        5′-GYGGAGAYGGAGTATAATATTATAYGTATTATTAAYGTTAYGTAGTTTTT-3′
  *IL28RA*     XM 417841       F            5′-GGGACACCGCTGATCGTTTAAGGATGTGCGAGGTAGAATATTG-3′
                               R            5′-CAAACCCTACAACAACCACATAAT-3′
                               Sequencing   5′-CCCTACAACAACCACATAA-3′
                               Assay        5′-TCRCTATATACTAACCRCCACRTTCCCAACAACRCACTAACRACTACAAC0A ATATTCTACCTCGCAC-3′
  *M0N2*       NM 001199605    F            5′-TTATTGCGGTAGGGGTTAATATT-3′
                               R            5′-GGGACACCGCTGATCGTTTA CAAACTAAACGCTATCCTAAACT-3′
                               Sequencing   5′-CGGTAGGGGTTAATATTTT-3′
                               Assay        5′-YGGGAGAYGTTAGYGGYGGGGATGGYGTTTTGTAGAGAGTAGTTTAGGATA-3′
  *THBS2*      NM 001001755    F            5′-GGGACACCGCTGATCGTTTA GGGTGTATGTAGAAAAGGGAATGT-3′
                               R            5′-TTCAACACGATACTATTCCTACCC-3′
                               Sequencing   5′-ACATAACTACATCTCCATAT-3′
                               Assay        5′-ACRTACRCTCCCACAATAAATAAAACAAACRACRACCRCTTAAACRTACAA ACATTCCCTTTTCTACATA C-3′
  *CD44*       NM_204860       F            5′-GTTTTTTTAAAATTTGTGTGGTTGT-3′
                               R            5′-GGGACACCGCTGATCGTTTA AAACTCCATCAAAAATCACACC-3′
                               Sequencing   5′-GGTTGTTTAGTTAGAATTTA-3′
                               Assay        5′-YGGTTTTTYGYGGTTTTTTTTGTTTTGTTTCGTAAT-3′
  *IL12*       NM_213588       F            5′-GTCGATGTCGTGTTTTGTTATGT-3′
                               R            5′-GGGACACCGCTGATCGTTTA CCACGAAATTCCCAACTCTCA-3′
                               Sequencing   5′-TTTTGTTCGATGAAATTG-3′
                               Assay        5′-ATGYGGGATYGGTGGTTGTYGTAGGAGTTGYGTTGTTTTTATGTYGGTGG AGGAGTAGG AGTTTTTTTTT-3′
  *LATS2*      XM417143        F            5′-GGGACACCGCTGATCGTTTATTTTGGTAGAAAGTTGGTGTGAAT-3′
                               R            5′-CACCATATAACACTTCCCTACCTC-3′
                               Sequencing   5′-CCTACCTCACAAAAACC-3′
                               Assay        5′-TCRCCCRTCTTACAAACRATTCACCRTCTCRCCATCTTCTCCCCCRCTCCT TCAACTCRACRAATTCACA CCAACTTTCTACCAAAA-3′
  *GH*         NM_204359       F            5′-GGGACACCGCTGATCGTTTA GATTGGTGTGGAAAGGAGGAAGA-3′
                               R            5′-CAAAAACAAATCGAACCCACAAC-3′
                               Sequencing   5′-CTCCTACAATTATCCATCC-3′
                               Assay        5′-CACRTTCTACCTCRTACRACTCAAAAATAAATATACTAAAACT-3′
  *IGF2*       NM_001030342    F            5′-AAGTATAACGTGTGGTAGAAGAAGAGTT-3′
                               R            5′-GGGACACCGCTGATCGTTTA TCGCCCTAACTTCCTCAACTACT-3′
                               Sequencing   5′-CGTGTGGTAGAAGAAGAGT-3′
                               Assay        5′-TYGTAGYGGTTGTAGYGGGAGGTGTTAGGTATTTTGYGTGTTYGTYGGTAT YGGTGGTAGGCGGAGGGGTTGTAAGT-3′
  *TNFSF10*    NM 204379       F            5′-GAGGGGAGGTTTAGGTTGGATATT-3′
                               R            5′-GGGACACCGCTGATCGTTTA ACCGCCCACATCCCTCAATA-3′
                               Sequencing   5′-GGGGTGGAGTAGTGGTATA-3′
                               Assay        5′-GTYGTTYGGGGAGYGGTGGAGTTATYGTTTTTGGAAGTGTTTAGAGTYGTGGGGATGTGGTATTGAGGGATGT-3′
  *H2Ac*       NM_001079475    F            5′-AGTGGGGGACGTGCGAAATA-3′
                               R            5′-GGGACACCGCTGATCGTTTA CCCCGCCCTTCCTCTTTTATAAC-3′
                               Sequencing   5′-TTATTGGGTAGATTTGGAT-3′
                               Assay        5′-TYGYGGYGTTATTGGTYGGAGYGAGTGAGAGAGTATATYGGTTAATYGGAAAGYGAGTYG GGTYGTTGYGGGAGGTTATAAAAGAGGAAG GGCG-3′
  *CIITA*      NC 006101.2     F            5′-CGGGAATTTTTACGTTAGGTTTATAGTG-3′
                               R            5′-GGGACACCGCTGATCGTTTAAACGCGAAACGAAAAAACTCCT-3′
                               Sequencing   5′-TTTTTACGTTAGGTTTATAG-3′
                               Assay        5′-TGTYGTYGYGGTATTTTAGTYGTTYGGTYGGGTTGYGGGGYGGTTTYGTT TTTTTTGGGGGYGGTTGTGGGAGCGGAGGAGTTTTTT-3′
  *FABP3*      NM 001030889    F            5′-AGAGGGGGAAATTGAGGTA-3′
                               R            5′-GGGACACCGCTGATCGTTTA AACACACACACACGATCC-3′
                               Sequencing   5′-GGGGGAAATTGAGGTA-3′
                               Assay        5′-YGGGAGYGTTYGTGGGGATAYGYGGGATCGTGTGTGTGTGTTGGGGGT-3′

*Y stands for C/T, and R stands for G/A. Bold Y or R in the assay sequence is the CpG sites analyzed in each region*.

###### 

**Primers for quantitative real-time RT-PCR**.

  Genes       Primers   Sequence
  ----------- --------- -----------------------------
  *ITG*β*5*   F         5′-GTTTGGGGAGACCTGTGAGA-3′
              R         5′-TCATCCTTGCAGTGCTTTTG-3′
  *H2Ac*      F         5′-CGGAAAGCAGGGCGGGAAG-3′
              R         5′-GTCAGGTACTCCAGCACGG-3′
  *DNMT1*     F         5′-CCACCAAAAGGAAATCAGAG-3′
              R         5′-TAATCCTCTTCTCATCTTGCT-3′
  *DNMT3a*    F         5′-ATGAACGAGAAGGAAGACATC-3′
              R         5′-GCAAAGAGGTGGCGGATCAC-3′
  *DNMT3b*    F         5′-CGTTACTTCTGGGGCAACCTC-3′
              R         5′-ATGACAGGGATGCTCCAGGAC-3′
  *GAPDH*     F         5′-GAGGGTAGTGAAGGCTGCTG-3′
              R         5′-ACCAGGAAACAAGCTTGACG-3′

###### 

**Promoter Methylation levels of L6~3~ and L7~2~ not challenged with MDV**.

  Genes        Lines   CpG sites      Note                                                                                                       
  ------------ ------- -------------- -------------- --------------- -------------- --------------- -------------- -------------- -------------- --------
  *LATS2*      L6~3~   0.73 ± 0.91    0.12 ± 0.41    3.60 ± 2.33     0.56 ± 0.84    1.19 ± 1.31     0.71 ± 1.30    1.13 ± 2.49    0.32 ± 0.64    
               L7~2~   0.78 ± 0.97    0.67 ± 0.88    3.20 ± 1.32     0.78 ± 0.89    1.30 ± 1.22     0.81 ± 1.27    2.09 ± 2.80    0.56 ± 0.70    
  *MON2*       L6~3~   1.04 ± 1.37    1.50 ± 1.48    1.59 ± 1.80     0.99 ± 1.80    0.57 ± 1010     N/A/A          N/A/A          N/A/A          
               L7~2~   1.94 ± 1.11    1.34 ± 1.50    2.47 ± 3.25     1.53 ± 2.09    1.01 ± 1.30     N/A/A          N/A/A          N/A/A          
  *IL28RA*     L6~3~   4.77 ± 1.14    7.91 ± 1.85    2.09 ± 1.47     5.00 ± 1.25    3.50 ± 0.81     N/A/A          N/A/A          N/A/A          
               L7~2~   3.90 ± 1.08    7.95 ± 1.34    2.49 ± 0.56     5.10 ± 1.75    3.90 ± 1.38     N/A/A          N/A/A          N/A/A          
  *STAT1*      L6~3~   1.41 ± 1.31    2.22 ± 1.22    2.97 ± 1.48     2.59 ± 1.76    1.26 ± 1.17     1.98 ± 1.27    N/A/A          N/A/A          
               L7~2~   1.06 ± 1.28    3.26 ± 1.93    2.91 ± 1.65     3.10 ± 0.70    0.71 ± 1.07     1.50 ± 1.47    N/A/A          N/A/A          
  *CD44*       L6~3~   1.53 ± 0.60    20.72 ± 7.08   0.58 ± 0.16     15.10 ± 3.39   N/A/A           N/A/A          N/A/A          N/A/A          
               L7~2~   1.94 ± 1.02    6.73 ± 1.43    3.04 ± 0.91     6.76 ± 0.93    N/A/A           N/A/A          N/A/A          N/A/A          
  *H2Ac*       L6~3~   4.33 ± 0.57    3.55 ± 0.59    21.51 ± 1.32    29.03 ± 1.76   14.83 ± 0.81    10.09 ± 0.74   N/A/A          N/A/A          
               L7~2~   7.81 ± 0.91    6.16 ± 1.02    31.18 ± 1.75    38.50 ± 1.25   20.48 ± 0.87    16.50 ± 0.87   N/A/A          N/A/A          
  *TNFSF10*    L6~3~   4.02 ± 0.90    9.92 ± 1.09    10.33 ± 1.67    10.63 ± 2.35   38.60 ± 2.04    N/A/A          N/A/A          N/A/A          
               L7~2~   5.48 ± 1.58    8.93 ± 3.23    13.15 ± 2.42    9.91 ± 3.54    25.07 ± 3.75    N/A/A          N/A/A          N/A/A          
  *IL12*       L6~3~   19.38 ± 6.42   12.38 ± 4.22   15.60 ± 3.94    17.02 ± 4.29   7.43 ± 1.76     N/A/A          N/A/A          N/A/A          
               L7~2~   24.25 ± 4.29   14.57 ± 3.30   18.30 ± 2.01    21.22 ± 4.25   8.78 ± 2.16     N/A/A          N/A/A          N/A/A          
  *FABP3*      L6~3~   35.99 ± 7.36   35.24 ± 4.20   48.05 ± 7.12    32.69 ± 4.39   4.16 ± 1.81     20.43 ± 8.12   N/A/A          N/A/A          
               L7~2~   28.22 ± 6.60   30.27 ± 8.05   39.98 ± 12.15   28.38 ± 7.52   4.85 ± 1.46     17.03 ± 5.14   N/A/A          N/A/A          
  *CIITA*      L6~3~   25.57 ± 4.55   29.20 ± 6.72   4.26 ± 3.64     3.22 ± 2.96    N/A/A           N/A/A          N/A/A          N/A/A          
               L7~2~   19.76 ± 7.59   24.70 ± 8.94   4.56 ± 4.72     4.30 ± 5.96    N/A/A           N/A/A          N/A/A          N/A/A          
  *ITGB5*      L6~3~   38.62 ± 4.45   46.81 ± 4.08   61.94 ± 4.47    44.06 ± 4.88   37.74 ± 1.32    39.63 ± 1.57   N/A/A          N/A/A          Inter.
               L7~2~   52.04 ± 4.62   61.32 ± 4.76   71.83 ± 3.54    56.37 ± 4.09   40.05 ± 1.86    41.53 ± 5.97   N/A/A          N/A/A          
  *THBS2*      L6~3~   34.31 ± 5.01   54.07 ± 6.46   32.32 ± 4.90    22.03 ± 3.13   11.37 ± 1.85    N/A/A          N/A/A          N/A/A          
               L7~2~   49.45 ± 5.16   70.68 ± 5.04   41.68 ± 4.63    30.91 ± 3.82   14.08 ± 1.45    N/A/A          N/A/A          N/A/A          
  *HDAC9*      L6~3~   24.83 ± 6.00   31.65 ± 6.03   51.50 ± 5.82    55.74 ± 4.78   40.77 ± 6.22    N/A/A          N/A/A          N/A/A          
               L7~2~   36.80 ± 5.36   45.83 ± 4.20   64.86 ± 6.47    68.25 ± 3.94   54.15 ± 3.48    N/A/A          N/A/A          N/A/A          
  *IGF2*       L6~3~   89.69 ± 4.08   89.25 ± 2.35   88.05 ± 3.85    77.81 ± 3.72   79.39 ± 3.46    49.77 ± 3.85   68.19 ± 7.40   88.95 ± 1.92   Hyper.
               L7~2~   91.55 ± 3.95   92.06 ± 2.54   89.78 ± 2.74    81.15 ± 4.68   82.37 ± 10.41   52.64 ± 5.77   72.41 ± 6.71   89.97 ± 2.02   
  *GH1*        L6~3~   63.12 ± 2.75   48.64 ± 2.51   80.64 ± 2.54    N/A/A          N/A/A           N/A/A          N/A/A          N/A/A          
               L7~2~   61.26 ± 2.19   45.13 ± 1.90   79.23 ± 1.91    N/A/A          N/A/A           N/A/A          N/A/A          N/A/A          
  *NK-lysin*   L6~3~   89.47 ± 2.33   42.98 ± 5.29   82.46 ± 2.20    78.32 ± 1.72   62.63 ± 2.16    N/A/A          N/A/A          N/A/A          
               L7~2~   91.79 ± 2.63   40.57 ± 5.47   80.53 ± 2.45    78.14 ± 1.88   66.56 ± 1.52    N/A/A          N/A/A          N/A/A          
  *TGFB3*      L6~3~   88.04 ± 1.60   90.98 ± 2.19   90.39 ± 2.28    80.86 ± 1.60   68.43 ± 2.13    74.39 ± 3.46   N/A/A          N/A/A          
               L7~2~   89.88 ± 2.59   92.91 ± 2.58   93.51 ± 2.66    82.90 ± 2.09   72.94 ± 3.09    77.00 ± 2.68   N/A/A          N/A/A          
  *CD82*       L6~3~   3.86 ± 1.56    5.24 ± 1.86    3.97 ± 1.61     3.98 ± 0.98    3.65 ± 2.02     1.88 ± 1.36    40.48 ± 5.54   52.78 ± 3.63   Hypo +
               L7~2~   3.16 ± 0.99    4.41 ± 1.31    3.59 ± 1.12     4.41 ± 1.40    2.69 ± 1.23     1.85 ± 1.27    41.22 ± 5.29   51.61 ± 2.67   Inter.

*Methylation level shown in each cell = mean ± STD*.

*Hypo., hypomethylation; Hyper., hypermethylation; Inter., intermediate methylation*.

*N/A, data not available*.

**N* = 12 for each group*.

###### 

**Promoter methylation level change at different CpG sites of genes after MDV challenge**.

  Gene name    Time points (dpi)   Lines   \% Methylation level change after MDV infection of different CpG sites                                                                          
  ------------ ------------------- ------- ------------------------------------------------------------------------ ------------ ------------ ------------ ----------- ---------- -------- ---------
  *GH*         5                   L6~3~   −5.09\*\*                                                                −7.44\*\*    −1.60                                                     
                                   L7~2~   3.29                                                                     1.50         4.07                                                      
               10                  L6~3~   2.73\*                                                                   −1.00        0.95                                                      
                                   L7~2~   3.75\*                                                                   1.04         −0.33                                                     
               21                  L6~3~   0.50                                                                     2.08\*       −0.09                                                     
                                   L7~2~   6.87\*                                                                   7.10\*\*     4.23\*\*                                                  
  *CD44*       5                   L6~3~   −0.23                                                                    0.71         −0.02        0.40                                         
                                   L7~2~   0.40                                                                     −4.25        −1.26        0.36                                         
               10                  L6~3~   −0.56                                                                    2.39         −0.13        −1.63                                        
                                   L7~2~   0.32                                                                     0.29         1.34         0.59                                         
               21                  L6~3~   0.03                                                                     −3.30        0.21         0.16                                         
                                   L7~2~   −0.77                                                                    −3.17\*\*    −1.57        1.39                                         
  *CIITA*      5                   L6~3~   4.41                                                                     −3.23        1.50         5.11                                         
                                   L7~2~   −11.86\*                                                                 −12.67       −2.78        −2.74                                        
               10                  L6~3~   −2.21                                                                    0.29         0.59         −1.60                                        
                                   L7~2~   1.04                                                                     0.28         1.19         0.24                                         
               21                  L6~3~   −10.17\*\*                                                               −6.12\*      0.34         1.27                                         
                                   L7~2~   −6.95\*\*                                                                −5.83\*      0.36         −1.18                                        
  *NK-lysin*   5                   L6~3~   4.24\*                                                                   18.21\*\*    6.25\*\*     6.72\*\*     1.20                            
                                   L7~2~   2.69                                                                     29.14\*\*    4.23         4.82\*       −0.40                           
               10                  L6~3~   1.61                                                                     8.62         1.63         3.46         1.28                            
                                   L7~2~   −1.03                                                                    7.60         1.63         1.33         2.90                            
               21                  L6~3~   −0.92\*                                                                  −3.59        −1.22        −1.55        −1.69\*\*                       
                                   L7~2~   −1.69\*\*                                                                −2.27        −2.06        −2.00\*      −1.99                           
  *THBS2*      5                   L6~3~   8.06                                                                     7.03         5.51         3.73         4.83                            
                                   L7~2~   −1.75                                                                    5.07         1.58         8.38         2.97                            
               10                  L6~3~   5.74                                                                     6.32         0.61         2.03         0.05                            
                                   L7~2~   −1.25                                                                    1.46         0.33         −0.43        1.35                            
               21                  L6~3~   −1.69                                                                    −1.38        2.49         1.50         2.07                            
                                   L7~2~   1.31                                                                     1.06         −0.20        −6.24        −0.06                           
  *M0N2*       5                   L6~3~   0.63                                                                     −1.33        −2.87\*      −1.69        −0.10                           
                                   L7~2~   −1.43                                                                    2.22         0.35         −3.06        −0.09                           
               10                  L6~3~   1.86                                                                     −0.62        0.59         0.75         0.41                            
                                   L7~2~   −1.17                                                                    −0.76        −5.96\*      0.42         −0.52                           
               21                  L6~3~   −0.33                                                                    0.43         0.56         0.29         −0.33                           
                                   L7~2~   0.94                                                                     −1.18        −0.63        0.64         −0.06                           
  *HDAC9*      5                   L6~3~   5.28                                                                     8.65         6.56         6.04         7.54                            
                                   L7~2~   3.37                                                                     11.67\*\*    −4.57        0.48         −3.20                           
               10                  L6~3~   −4.07                                                                    1.41         3.86         −2.11        3.13                            
                                   L7~2~   −1.01                                                                    0.17         3.47         0.07         −1.60                           
               21                  L6~3~   3.18                                                                     1.08         3.80         2.90         4.86                            
                                   L7~2~   12.56\*\*                                                                7.00\*\*     4.48         4.59         10.99\*\*                       
  *FABP3*      5                   L6~3~   7.07                                                                     9.34\*       15.81\*      8.58\*       3.22\*                          
                                   L7~2~   7.75                                                                     7.22         10.96        8.09         0.13                            
               10                  L6~3~   3.43                                                                     4.52         8.48         4.50         0.92                            
                                   L7~2~   −9.44\*                                                                  −11.67\*\*   −11.80\*\*   −10.82\*\*   −2.31\*\*                       
               21                  L6~3~   −8.35                                                                    −1.06        −2.23        0.03         2.81                            
                                   L7~2~   5.40                                                                     4.11         7.09         4.15         2.74                            
  *IL28RA*     5                   L6~3~   −1.87                                                                    −3.97\*      −0.54        −0.92        −0.46                           
                                   L7~2~   −2.75\*                                                                  −0.64        −1.12\*\*    −1.80        1.50                            
               10                  L6~3~   −2.05\*\*                                                                −0.60        −0.77        −0.65        0.02                            
                                   L7~2~   −1.67\*                                                                  −1.01        0.07         −1.15        0.70                            
               21                  L6~3~   0.81                                                                     0.03         1.20         1.41         0.04                            
                                   L7~2~   0.11                                                                     0.65         −0.58        −0.12        0.21                            
  *IL12*       5                   L6~3~   3.19\*                                                                   4.27         −0.42        0.66         −1.46\*                         
                                   L7~2~   −0.68                                                                    −0.68        0.13         −4.91        −1.43                           
               10                  L6~3~   0.39                                                                     −0.88        0.60         −3.44        −0.28                           
                                   L7~2~   −1.07                                                                    −4.03        −1.05        −5.39        −1.00                           
               21                  L6~3~   −2.02                                                                    −3.49        −3.58        0.12         −0.32                           
                                   L7~2~   3.06                                                                     1.85         −0.17        −3.05        1.08                            
  *TNFSF10*    5                   L6~3~   0.23                                                                     −1.73\*      −1.70        −1.24        −1.11                           
                                   L7~2~   −0.25                                                                    −2.79\*      −3.72\*      −1.43        −2.24                           
               10                  L6~3~   1.23                                                                     0.48         −0.19        0.81         −2.94                           
                                   L7~2~   −1.01                                                                    0.68         −1.19        0.06         1.80                            
               21                  L6~3~   0.38                                                                     0.12         0.19         −1.29        −1.54                           
                                   L7~2~   −1.37                                                                    2.79         −2.24        2.07         3.67                            
  *ITGB5*      5                   L6~3~   21.99\*\*                                                                24.91\*\*    25.41\*\*    21.58\*\*    1.54\*      0.38                
                                   L7~2~   16.68\*\*                                                                20.25\*\*    17.04\*\*    15.07\*\*    1.73        −0.77               
               10                  L6~3~   3.73                                                                     −0.14        −3.03        −1.15        −0.24       −2.14               
                                   L7~2~   −0.81                                                                    −2.01        −0.54        −1.81        −1.25       −2.76               
               21                  L6~3~   6.85                                                                     7.81         5.15         6.66         2.51        1.05                
                                   L7~2~   8.92                                                                     5.84         5.91         7.19         2.30        1.75                
  *STAT1*      5                   L6~3~   −1.18                                                                    −1.20        −1.13        −1.69        −0.30       −0.19               
                                   L7~2~   0.77                                                                     −1.10        0.23         −0.48        2.05\*      1.07                
               10                  L6~3~   1.51\*                                                                   −0.35        −0.55        2.24\*\*     −0.62       0.64                
                                   L7~2~   0.12                                                                     −0.86        0.01         1.39\*\*     −0.36       0.53                
               21                  L6~3~   0.95                                                                     −1.35        −1.98        −0.10        3.69\*      1.46                
                                   L7~2~   0.58                                                                     −3.86\*      −1.37        −1.86\*      1.42        2.08\*              
  *TGFB3*      5                   L6~3~   −0.44                                                                    4.22\*\*     5.32         0.25\*\*     6.90        5.63                
                                   L7~2~   3.62                                                                     2.66         2.97\*       2.38         2.15        −1.95               
               10                  L6~3~   1.34                                                                     0.84         −0.85\*\*    3.36\*\*     5.54        3.20                
                                   L7~2~   −0.57                                                                    −2.24        −0.10        1.58         4.74        1.38                
               21                  L6~3~   2.38                                                                     3.58         3.92\*       −0.33        −1.25       −4.07               
                                   L7~2~   −0.19                                                                    0.69         −0.34        −1.03        0.80        −0.13               
  *H2AC*       5                   L6~3~   0.63                                                                     0.65\*       2.26         1.26         1.26        0.60                
                                   L7~2~   2.79                                                                     1.25         4.58         3.69\*       1.83        1.55                
               10                  L6~3~   1.14                                                                     1.13         4.78         4.98         2.27\*      0.85\*\*            
                                   L7~2~   −0.15                                                                    0.14         −1.76\*\*    −1.40        0.12        −0.28               
               21                  L6~3~   0.60                                                                     0.25         0.95         1.61         0.22        1.04                
                                   L7~2~   −1.47\*                                                                  0.87         −3.09\*\*    −3.88\*\*    −0.72       0.13                
  *CD82*       5                   L6~3~   1.85                                                                     2.32         0.33         0.50         0.18        −0.47      −4.79    −2.36
                                   L7~2~   2.06                                                                     0.04         2.27         0.39         −0.57       −0.15      −5.52    −2.09
               10                  L6~3~   −1.87\*                                                                  −2.07\*\*    −1.42        0.92         −2.17       3.88\*     1.60     −0.24
                                   L7~2~   0.55                                                                     −0.80        −1.08        0.00         0.86        2.65       0.09     1.27
               21                  L6~3~   0.21                                                                     0.88\*       −0.18        0.47         −0.50       0.44       −0.85    −1.30\*
                                   L7~2~   2.01\*\*                                                                 0.94\*       1.19         3.10\*\*     0.06        1.48       −1.77    −0.47
  *IGF2*       5                   L6~3~   0.02\*                                                                   2.83         0.16         3.50         −0.32       3.14       6.32\*   2.45\*
                                   L7~2~   2.19                                                                     1.47         0.82         3.70         −1.45       3.28       5.75     0.53
               10                  L6~3~   −1.36                                                                    1.05         1.93         2.18         2.69        3.44       0.49     0.30
                                   L7~2~   −4.09                                                                    −1.95        −1.67        3.24         4.55\*      3.60       −0.21    0.02
               21                  L6~3~   0.34                                                                     0.64         −0.12        0.79         1.62        2.33       −3.51    0.22
                                   L7~2~   −1.23                                                                    0.10         −1.18        −1.32        4.91        5.46       2.08     −0.60
  *LATS2*      5                   L6~3~   −0.21                                                                    1.04         −0.87        1.08         0.09        1.14       1.57     0.52
                                   L7~2~   0.32                                                                     0.25         −0.33        0.81         0.94        1.42       −1.65    0.48
               10                  L6~3~   −0.02                                                                    0.27         −0.26        0.24         −0.87       −0.23      0.85     −0.03
                                   L7~2~   0.77                                                                     0.74         0.82         0.42         −0.27       0.55       0.41     0.38
               21                  L6~3~   1.64\*                                                                   0.67         0.80         0.62         0.69        0.48       1.31     0.60
                                   L7~2~   1.90\*                                                                   0.74         −0.22        0.70         0.35        0.02       1.15     0.84

*\**P* \< 0.05, \*\**P* \< 0.01*.

![**Promoter methylation change during MDV life cycle in *GH* (A), *HDAC9* (B), *CIITA* (C), *STAT1* (D), *H2Ac* (E), *LATS2* (F), and *FABP3* (G)** The methylation change within lines was the methylation changed after MDV infection compared with the promoter methylation level before MDV infection. *N *= 4 for each group.](fgene-03-00020-a001){#FA1}
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